GenScript - GenScript Biotech Global Forum London 2025

Introduction

The field of gene and cell therapy is experiencing unprecedented growth, driven by groundbreaking innovations in life sciences, medicine, and robust investment from global capital markets. To foster progress in this transformative field, the GenScript Biotech Global Forum London 2025 will convene on Thursday, 20 November 2025 in London, held in conjunction with the Jefferies London Healthcare Conference. With four successful iterations in San Francisco and London, the GenScript Biotech Global Industry Forum has established itself as a premier gathering for top minds in cell and gene therapy.

Under the theme THE NEXT ERA OF CGT IS HERE, we are honored to invite leading experts from academia, industry, investment, and regulatory agencies to discuss the latest advancements in research, technological breakthroughs and evolving regulatory landscapes. This forum will bring together global thought leaders united in the mission to accelerate therapies that improve patient lives.

We would like to extend to you a cordial invitation to join your peers at this important event in London in November 2025.

Agenda

13:30-13:45

Opening Remarks

13:45-14:25

Keynote Speech

14:25-15:05

Panel Discussion: Navigating the Future of Cell Therapy: Evaluating Varied Pathways in Cell Therapy Innovation for Comprehensive Sector Insights

15:05-15:45

Keynote Speech

15:45-16:25

Panel Discussion: Gene Therapy and mRNA Therapeutics

16:25-17:05

Panel Discussion: From Lab to Patient: Overcoming CMC Barriers in Cell and Gene Therapy Manufacturing

17:05-17:45

Keynote Speech

17:45-18:25

Panel Discussion: Innovation and Investment for CGT

18:25-18:30

Closing Remarks

18:30-20:30

Reception

Registration

Pre-registration: 50 GBP /Person（before November 15, 2025）
On-site Registration: 100 GBP /Person (November 20, 2025)
Contact us at [email protected]

Keynote Speakers

Craig Mello, Ph.D.

Blais University Chair in Molecular Medicine, and co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School, 2006 Nobel Prize in Physiology or Medicine

Miguel Forte, M.D., Ph.D.

President and Board of Directors Chair of the International Society of Cell and Gene Therapy (ISCT), CEO and Co-Founder of Kiji Therapeutics, Executive Chairman of Akatsuki Therapeutics

Carl June, M.D.

Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine, Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, Director of the Parker Institute for Cancer Immunotherapy, University of Pennsylvania

Speakers

Dima Al-hadithi, Ph.D.

Partner-CMC, RareGenix/Minaret Consulting Ltd

Michael Brinkman

Managing Director and Joint US Head of Biopharmaceuticals Investment Banking, Jefferies

Michiel Bröker, M.D.

Managing Director and Global Head of Pharma, UBS

Luigi Calzolai, Ph.D.

Scientific Officer, European Commission Joint Research Centre (JRC)

Anna Cereseto, Ph.D.

Head of Lab for Advanced Genome Editing Technologies, University of Trento, Co-Founder, Alia Therapeutics

Matthieu Coutet

Partner, Sofinnova Biovelocita Strategy

Daniela Couto, Ph.D.

General Partner, BioGeneration Ventures

Jonathan Esensten, M.D., Ph.D.

Senior Advisor, Multiply Labs, and Director, Advanced Biotherapy Center, Sheba Medical Center

Graeme Fielder, Ph.D.

Chief Operating Officer, AviadoBio

Miroslav Gasparek

CEO and Co-founder, Sensible Biotechnologies

Marten Hansen, Ph.D.

Head of the Laboratory for Cell Therapy at the Sanquin Blood Supply Foundation, CEO of the Amsterdam Cell Therapy Center, Secretary of the Dutch-Flemish ATMP Working Party